[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653484":3},{"organization":4,"outcomesModule":7,"designInfo":49,"detailedDescription":11,"studyPopulation":11,"armGroups":55,"interventions":61,"overallOfficials":66,"centralContacts":70,"locations":79,"responsibleParty":154,"collaborators":11,"id":156,"slug":157,"hasResults":158,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":11,"eligibilityCriteria":162,"healthyVolunteers":158,"sex":163,"minAge":164,"maxAge":11,"enrollmentInfo":165,"targetDuration":11,"studyType":168,"phases":169,"briefSummary":171,"conditions":172,"keywords":11,"overallStatus":82,"whyStopped":11,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":183},{"fullName":5,"class":6},"Ono Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Dose-limiting toxicities（DLT）",null,"From first dose through completion of the DLT evaluation period (approximately 21 days)",{"measure":14,"description":11,"timeFrame":15},"Adverse event (AE)","Approximately 6 months",[17,19,21,23,25,27,29,31,33,35,37,39,41,43,45,47],{"measure":18,"description":11,"timeFrame":15},"Area under the Plasma Concentration versus Time Curve (AUC)",{"measure":20,"description":11,"timeFrame":15},"Cmax",{"measure":22,"description":11,"timeFrame":15},"Tmax",{"measure":24,"description":11,"timeFrame":15},"Terminal elimination half-life（T1\u002F2）",{"measure":26,"description":11,"timeFrame":15},"Ctrough",{"measure":28,"description":11,"timeFrame":15},"CL",{"measure":30,"description":11,"timeFrame":15},"Volume of distribution at steady state（Vss）",{"measure":32,"description":11,"timeFrame":15},"Objective Response Rate (ORR)",{"measure":34,"description":11,"timeFrame":15},"Disease Control Rate (DCR)",{"measure":36,"description":11,"timeFrame":15},"Best overall response（BOR）",{"measure":38,"description":11,"timeFrame":15},"Duration of Response (DOR)",{"measure":40,"description":11,"timeFrame":15},"Progression-Free Survival (PFS)",{"measure":42,"description":11,"timeFrame":15},"Overall Survival (OS)",{"measure":44,"description":11,"timeFrame":15},"Time to Response (TTR)",{"measure":46,"description":11,"timeFrame":15},"Percent change from baseline in the sum of diameters of target lesions",{"measure":48,"description":11,"timeFrame":15},"Best percent change from baseline in the sum of diameters of target lesions",{"allocation":50,"interventionModel":51,"interventionModelDescription":11,"primaryPurpose":52,"observationalModel":11,"timePerspective":11,"maskingInfo":53},"NA","SINGLE_GROUP","TREATMENT",{"masking":54,"maskingDescription":11,"whoMasked":11},"NONE",[56],{"label":57,"type":58,"description":11,"interventionNames":59},"ONO-7429","EXPERIMENTAL",[60],"Drug: ONO-7429",[62],{"type":63,"name":57,"description":64,"armGroupLabels":65,"otherNames":11},"DRUG","Specified dose on specified days",[57],[67],{"name":68,"affiliation":5,"role":69},"Project Leader","STUDY_DIRECTOR",[71,76],{"name":72,"role":73,"phone":74,"phoneExt":11,"email":75},"North America Clinical Trial Support Desk","CONTACT","+18665877745(Toll-Free)","clinical_trial@ono-pharma.com",{"name":77,"role":73,"phone":78,"phoneExt":11,"email":75},"International Clinical Trial Support Desk","+17162141777(Standard)",[80,93,102,110,119,126,134,143,147,151],{"facility":81,"status":82,"city":83,"state":84,"zip":11,"country":85,"countryCode":86,"cosmosGeoPoint":87,"geoPoint":92,"contacts":11},"National Cancer Center Hospital East","RECRUITING","Kashiwa","Chiba","Japan","JP",{"type":88,"coordinates":89},"Point",[90,91],139.97732,35.86224,{"lat":91,"lon":90},{"facility":94,"status":82,"city":95,"state":96,"zip":11,"country":85,"countryCode":86,"cosmosGeoPoint":97,"geoPoint":101,"contacts":11},"Gunma University Hospital","Maebashi","Gunma",{"type":88,"coordinates":98},[99,100],139.08333,36.4,{"lat":100,"lon":99},{"facility":103,"status":82,"city":104,"state":104,"zip":11,"country":85,"countryCode":86,"cosmosGeoPoint":105,"geoPoint":109,"contacts":11},"Niigata Cancer Center Hospital","Niigata",{"type":88,"coordinates":106},[107,108],139.04125,37.92259,{"lat":108,"lon":107},{"facility":111,"status":82,"city":112,"state":113,"zip":11,"country":85,"countryCode":86,"cosmosGeoPoint":114,"geoPoint":118,"contacts":11},"Kansai Medical University Hospital","Hirakata","Osaka",{"type":88,"coordinates":115},[116,117],135.64914,34.81352,{"lat":117,"lon":116},{"facility":120,"status":82,"city":113,"state":113,"zip":11,"country":85,"countryCode":86,"cosmosGeoPoint":121,"geoPoint":125,"contacts":11},"Osaka International Cancer Institute",{"type":88,"coordinates":122},[123,124],135.50107,34.69379,{"lat":124,"lon":123},{"facility":127,"status":82,"city":128,"state":113,"zip":11,"country":85,"countryCode":86,"cosmosGeoPoint":129,"geoPoint":133,"contacts":11},"Kindai University Hospital","Sakai",{"type":88,"coordinates":130},[131,132],135.46653,34.58216,{"lat":132,"lon":131},{"facility":135,"status":82,"city":136,"state":137,"zip":11,"country":85,"countryCode":86,"cosmosGeoPoint":138,"geoPoint":142,"contacts":11},"Saitama Medical University International Medical Center","Hidaka","Saitama",{"type":88,"coordinates":139},[140,141],139.36233,35.91664,{"lat":141,"lon":140},{"facility":144,"status":82,"city":145,"state":146,"zip":11,"country":85,"countryCode":86,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Shizuoka Cancer Center","Sunto-gun","Shizuoka",{"facility":148,"status":82,"city":149,"state":150,"zip":11,"country":85,"countryCode":86,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"National Cancer Center Hospital","Chuo-ku","Tokyo",{"facility":152,"status":82,"city":153,"state":150,"zip":11,"country":85,"countryCode":86,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"The Cancer Institute Hospital of JFCR","Koto-ku",{"type":155,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100653484","phase-1-a-study-of-ono-7429-in-participants-with-unresectable-advanced-or-recurrent-solid-tumors-100653484",false,"NCT07787208","A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors","A Phase 1, Open-label, Dose Escalation Study to Investigate the Safety and Tolerability of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors","Inclusion Criteria:\n\n1. Participants with histologically or cytologically confirmed unresectable advanced or recurrent solid tumors.\n2. Participants who are refractory or intolerant to standard therapy.\n3. Participants with Eastern Cooperative Oncology Group Performance Status 0 or 1.\n4. Participants with tumor tissue samples available for biomarker testing.\n\nExclusion Criteria:\n\n1. Participants with a history or presence of severe hypersensitivity to any other antibody agents.\n2. Participants with pericardial fluid, pleural effusion or ascites requiring treatment\n3. Participants with uncontrolled tumor-related pain\n4. Participants with severe peritoneal dissemination.\n5. Participants with multiple primary cancers.\n6. Participants with a history or presence of ILD or pulmonary fibrosis.","ALL","18 Years",{"count":166,"type":167},80,"ESTIMATED","INTERVENTIONAL",[170],"PHASE1","This study is to evaluate the tolerability and safety of ONO-7429 in participants with unresectable advanced or recurrent solid tumors.",[173],"Solid Tumors","2026-08-24",{"date":176,"type":177},"2026-08-26","ACTUAL",{"date":179,"type":177},"2026-06-19",{"date":181,"type":167},"2030-03",{"name":5,"class":6},10]